Applied Therapeutics (APLT) was Downgraded to a Hold Rating at Barclays

Applied Therapeutics (APLTResearch Report) received a Hold rating and a $7.00 price target from Barclays analyst Carter Gould on December 31. The company’s shares closed last Tuesday at $5.82.

According to TipRanks.com, Gould is a 3-star analyst with an average return of 5.3% and a 46.7% success rate. Gould covers the Healthcare sector, focusing on stocks such as Reata Pharmaceuticals, Travere Therapeutics, and Molecular Templates.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Applied Therapeutics with a $7.00 average price target.

See the top stocks recommended by analysts >>

The company has a one-year high of $29.80 and a one-year low of $8.76. Currently, Applied Therapeutics has an average volume of 190.7K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY.

Read More on APLT:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed